- Home
- KEY vs VTRS Comparison
KEY vs VTRS Comparison
Compare KEY & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KEY | VTRS |
|---|---|---|
| Founded | 1825 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.4B | 21.0B |
| IPO Year | 2005 | 2019 |
Fundamental Metrics
Financial Performance| Metric | KEY | VTRS |
|---|---|---|
| Price | $21.12 | $18.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 12 |
| Target Price | ★ $25.11 | $19.70 |
| AVG Volume (30 Days) | ★ 16.4M | 8.5M |
| Earning Date | 10-20-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.87% | 2.60% |
| EPS Growth | ★ 575.00 | N/A |
| EPS | ★ 0.88 | 0.05 |
| Revenue | $7,513,000,000.00 | ★ $14,299,900,000.00 |
| Revenue This Year | $7.78 | $3.44 |
| Revenue Next Year | $6.90 | $1.68 |
| P/E Ratio | ★ $24.06 | $370.63 |
| Revenue Growth | ★ 62.65 | N/A |
| 52 Week Low | $16.91 | $9.92 |
| 52 Week High | $24.07 | $18.75 |
Technical Indicators
Market Signals| Indicator | KEY | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 60.23 | 55.16 |
| Support Level | $20.48 | $15.94 |
| Resistance Level | $22.25 | $18.30 |
| Average True Range (ATR) | 0.39 | 0.47 |
| MACD | 0.21 | 0.03 |
| Stochastic Oscillator | 91.74 | 64.78 |
Price Performance
Historical ComparisonAbout KEY KeyCorp
With assets of around $190 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its three largest markets: Ohio, New York, and Washington. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.